November 2004
Psychiatric Annals;Nov2004, Vol. 34 Issue 11, p816
Academic Journal
The article focuses on a new analysis which reveals that patients with anxiety and depression symptoms fare better when they undergo both pharmacotherapy and psychotherapy treatment in combination. Patients who use both medications and at least 13 sessions of talk therapy had the highest outcome score of 80, while those who reported their main treatment as one to six therapy sessions score at 70, the lowest score.


Related Articles

  • Effectiveness of Problem-Solving Therapy for Older, Primary Care Patients With Depression: Results From the IMPACT Project. Arean, Patricia; Hegel, Mark; Vannoy, Steven; Ming-Yu Fan; Unuzter, Jurgen // Gerontologist;Jun2008, Vol. 48 Issue 3, p311 

    Purpose: We compared a primary-care-based psychotherapy, that is, problem-solving therapy for primary care (PST-PC), to community-based psychotherapy in treating late-life major depression and dysthymia. Design and Methods: The data here are from the IMPACT study, which compared collaborative...

  • how to lift your mood. Khalsa, Karta Purkh Singh // Better Nutrition;Feb2008, Vol. 70 Issue 2, p32 

    The article offers natural therapies for depression. According to the author, depression is a life-threatening illness that must be treated by medical experts. Researchers confirm that depression can worsen health more than arthritis, asthma, and diabetes. It is conventionally treated with...

  • Treatment of depressed in-patients. Cognitive therapy plus medication, relaxation plus medication, and medication alone. Bowers, Wayne A.; Bowers, W A // British Journal of Psychiatry;Jan90, Vol. 156, p73 

    Thirty in-patients received one of three treatments - medication (nortriptyline) alone (MA), relaxation therapy plus medication (RT&M), or cognitive therapy plus medication (CT&M) (each n = 10) - along with ward milieu. The relaxation and cognitive therapy groups participated in 12 therapy...

  • Influence of Patients’ Requests for Direct-to-Consumer Advertised Antidepressants: A Randomized Controlled Trial. Kravitz, Richard L.; Epstein, Ronald M.; Feldman, Mitchell D.; Franz, Carol E.; Azari, Rahman; Wilkes, Michael S.; Hinton, Ladson; Franks, Peter // JAMA: Journal of the American Medical Association;4/27/2005, Vol. 293 Issue 16, p1995 

    Context: Direct-to-consumer (DTC) advertising of prescription drugs in the United States is both ubiquitous and controversial. Critics charge that it leads to overprescribing, while proponents counter that it helps avert underuse of effective treatments, especially for conditions that are poorly...

  • Influence of socio-economic deprivation on the prevalence and outcome of depression in primary care: the Hampshire Depression Project. Ostler, K.; Thompson, C.; Kinmonth, A.-l. K.; Peveler, R. C.; Stevens, L.; Stevens, A.; Kinmonth, A L // British Journal of Psychiatry;Jan2001, Vol. 178, p12 

    Background: Health inequalities exist for many disorders, but the contribution of deprivation to the prevalence and outcome of depressive symptoms in primary care populations has been infrequently studied.Aims: To examine the influence of Jarman under-privileged area...

  • Screening for adjustment disorders and major depressive disorders in cancer in-patients. Razavi, Darius; Delvaux, Nicole; Farvacques, Christine; Robaye, Edmond; Razavi, D; Delvaux, N; Farvacques, C; Robaye, E // British Journal of Psychiatry;Jan90, Vol. 156, p79 

    The Hospital Anxiety and Depression Scale (HADS), a four-point, 14-item questionnaire, was tested as a screening method for adjustment disorders and major depressive disorders in a sample of 210 cancer in-patients. A receiver operating characteristic (ROC) analysis was performed, giving the...

  • Escitalopram ahead of the game in MDD.  // PharmacoEconomics & Outcomes News;6/4/2005, Issue 479, p11 

    Discusses research being done on the cost effectiveness of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in Great Britain. Reference to a study by A. G. Wade et al, published in the April 2005 issue of "Current Medical Research and...

  • Reducing the Trial and Error Factor in Antidepressant Treatment. Sussman, Norman // Primary Psychiatry;May2010, Vol. 17 Issue 5, p16 

    The article focuses on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, which identities which treatments work best if the first treatment with medication fails to have an acceptable response, and the Combining Medication to Enhance Depression Outcomes (CO-MED), which...

  • Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Stein, George; Bernadt, Morris; Stein, G; Bernadt, M // British Journal of Psychiatry;May93, Vol. 162, p634 

    Thirty-four patients with tricyclic-resistant depressive illness took part in a nine-week, double-blind, placebo-controlled trial of lithium augmentation. In addition to the maximum tolerated doses of their tricyclic antidepressant, the experimental group (n = 16) received 250 mg lithium daily...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics